Table of Contents

March 01, 2004; Volume 71, Issue 3
  • From the Editor

      • Fish oil is no snake oil

        John D. Clough, MD
        • Cleveland Clinic Journal of Medicine March 2004, 71 (3) 174;
        • That cod-liver oil I took as a child, though foul tasting, may have been good for my heart.

  • 1-Minute Consult

  • Review

      • Spondyloarthropathies: Using presentation to make the diagnosis

        Siwat Kiratiseavee, MD and Lawrence H. Brent
        • Cleveland Clinic Journal of Medicine March 2004, 71 (3) 184-206;
        • Spondylitis is easy to miss and is often falsely assumed to be “just back pain.” Inhibitors of tumor necrosis factor show promise as treatments, but data are still limited.

      • Fish oil supplementation: Evidence for health benefits

        William S. Harris, PhD
        • Cleveland Clinic Journal of Medicine March 2004, 71 (3) 208-221;
        • We have solid and compelling evidence that two long-chain omega-3 fatty acids help prevent coronary heart disease.

      • Hearing loss is often undiscovered, but screening is easy

        Craig W. Newman, PhD and Sharon A. Sandridge, PhD
        • Cleveland Clinic Journal of Medicine March 2004, 71 (3) 225-232;
        • Does your patient need a hearing aid? Primary care physicians—the gatekeepers of audiologic care—can play a more active role in improving the hearing of their adult patients.

      • Fitz-Hugh-Curtis syndrome: A diagnosis to consider in women with right upper quadrant pain

        Nadja G. Peter, MD, Liana R. Clark, MD and Jeffrey R. Jaeger, MD
        • Cleveland Clinic Journal of Medicine March 2004, 71 (3) 233-239;
        • Does your patient need a hearing aid? Primary care physicians—the gatekeepers of audiologic care—can play a more active role in improving the hearing of their adult patients.

      • What physicians can do to prevent suicide

        David J. Muzina, MD
        • Cleveland Clinic Journal of Medicine March 2004, 71 (3) 242-250;
        • No one can predict whether any given patient will or will not attempt suicide, but we should notice when a patient might be at risk—and not be afraid to ask about it.

      • TOC Icon

        Omalizumab: Where does it fit into current asthma management?

        Todd E. Rambasek, MD, David M. Lang, MD and Mani S. Kavuru, MD
        • Cleveland Clinic Journal of Medicine March 2004, 71 (3) 251-261;
        • This drug offers substantial promise, but owing to its cost and other limitations, it is not a first-line therapy.